KR20020016806A - Ｉｌ-8 수용체 길항제 - Google Patents

Ｉｌ-8 수용체 길항제 Download PDF

Info

Publication number: KR20020016806A
Authority: KR; South Korea
Prior art keywords: alkyl; aryl; heteroaryl; optionally substituted; alkenyl
Prior art date: 1999-05-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

KR1020017015176A

Other languages

English (en)

Korean (ko)

Inventor

마이클 알. 팔로비치

캐서린 엘. 위도우슨

Original Assignee

스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스

스미스클라인 비참 코포레이션

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-28

Filing date

2000-05-26

Publication date

2002-03-06

2000-05-26 Application filed by 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스, 스미스클라인 비참 코포레이션 filed Critical 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스

2002-03-06 Publication of KR20020016806A publication Critical patent/KR20020016806A/ko

Status Withdrawn legal-status Critical Current

Links

108090001007 Interleukin-8 Proteins 0.000 title abstract description 56
239000002464 receptor antagonist Substances 0.000 title 1
229940044551 receptor antagonist Drugs 0.000 title 1
201000010099 disease Diseases 0.000 claims abstract description 27
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 27
102000019034 Chemokines Human genes 0.000 claims abstract description 23
108010012236 Chemokines Proteins 0.000 claims abstract description 23
230000001404 mediated effect Effects 0.000 claims abstract description 12
125000000217 alkyl group Chemical group 0.000 claims description 77
150000001875 compounds Chemical class 0.000 claims description 55
125000001072 heteroaryl group Chemical group 0.000 claims description 35
125000000623 heterocyclic group Chemical group 0.000 claims description 34
125000003118 aryl group Chemical group 0.000 claims description 30
229910052739 hydrogen Inorganic materials 0.000 claims description 19
238000000034 method Methods 0.000 claims description 19
125000003545 alkoxy group Chemical group 0.000 claims description 18
125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 16
239000001257 hydrogen Substances 0.000 claims description 16
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
229910052757 nitrogen Inorganic materials 0.000 claims description 10
150000003839 salts Chemical class 0.000 claims description 10
125000003107 substituted aryl group Chemical group 0.000 claims description 10
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
150000001412 amines Chemical class 0.000 claims description 8
102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 8
108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 8
229910052760 oxygen Inorganic materials 0.000 claims description 8
229910052717 sulfur Chemical group 0.000 claims description 8
125000003342 alkenyl group Chemical group 0.000 claims description 7
229910052736 halogen Inorganic materials 0.000 claims description 7
150000002367 halogens Chemical class 0.000 claims description 7
241000124008 Mammalia Species 0.000 claims description 6
206010040070 Septic Shock Diseases 0.000 claims description 6
125000004446 heteroarylalkyl group Chemical group 0.000 claims description 6
125000005842 heteroatom Chemical group 0.000 claims description 6
150000002431 hydrogen Chemical class 0.000 claims description 6
125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 claims description 6
125000003710 aryl alkyl group Chemical group 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
IVRGZEWHYUGRPZ-UHFFFAOYSA-N 1-(2-bromophenyl)-2-(chloromethylsulfonyl)-3-(4-cyano-2-hydroxyphenyl)guanidine Chemical compound OC1=CC(C#N)=CC=C1NC(=NS(=O)(=O)CCl)NC1=CC=CC=C1Br IVRGZEWHYUGRPZ-UHFFFAOYSA-N 0.000 claims description 4
SBBMELSLKPNWSX-UHFFFAOYSA-N 1-(2-bromophenyl)-3-(4-cyano-2-hydroxyphenyl)-2-(2,2-dimethoxyethyl)guanidine Chemical compound C=1C=CC=C(Br)C=1NC(=NCC(OC)OC)NC1=CC=C(C#N)C=C1O SBBMELSLKPNWSX-UHFFFAOYSA-N 0.000 claims description 4
GTHBAMARALJPMG-UHFFFAOYSA-N 4-[[1-(2-bromophenyl)imidazol-2-yl]amino]-3-hydroxybenzonitrile Chemical compound OC1=CC(C#N)=CC=C1NC1=NC=CN1C1=CC=CC=C1Br GTHBAMARALJPMG-UHFFFAOYSA-N 0.000 claims description 4
CDMONYVRPGEPCD-UHFFFAOYSA-N C=1C=CC=C(Br)C=1NC(=NCCO)NC1=CC=C(C#N)C=C1O Chemical compound C=1C=CC=C(Br)C=1NC(=NCCO)NC1=CC=C(C#N)C=C1O CDMONYVRPGEPCD-UHFFFAOYSA-N 0.000 claims description 4
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
125000004104 aryloxy group Chemical group 0.000 claims description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
150000001540 azides Chemical class 0.000 claims description 4
229910052799 carbon Inorganic materials 0.000 claims description 4
125000004093 cyano group Chemical group *C#N 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
239000001301 oxygen Substances 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
239000011593 sulfur Chemical group 0.000 claims description 4
PNIRPIRVDVRDBV-UHFFFAOYSA-N 4-[[1-(2-bromophenyl)-4,5-dihydroimidazol-2-yl]amino]-3-hydroxybenzonitrile Chemical compound OC1=CC(C#N)=CC=C1NC1=NCCN1C1=CC=CC=C1Br PNIRPIRVDVRDBV-UHFFFAOYSA-N 0.000 claims description 3
NBYLNCPJFMZLDQ-UHFFFAOYSA-N 4-[[1-(2-bromophenyl)-5-methoxy-4,5-dihydroimidazol-2-yl]amino]-3-hydroxybenzonitrile Chemical compound C=1C=CC=C(Br)C=1N1C(OC)CN=C1NC1=CC=C(C#N)C=C1O NBYLNCPJFMZLDQ-UHFFFAOYSA-N 0.000 claims description 3
AONNROPSWQKAOE-UHFFFAOYSA-N 4-[[1-(2-bromophenyl)-5-oxo-4h-imidazol-2-yl]amino]-3-hydroxybenzonitrile Chemical compound OC1=CC(C#N)=CC=C1NC1=NCC(=O)N1C1=CC=CC=C1Br AONNROPSWQKAOE-UHFFFAOYSA-N 0.000 claims description 3
201000001320 Atherosclerosis Diseases 0.000 claims description 3
206010010904 Convulsion Diseases 0.000 claims description 3
201000004681 Psoriasis Diseases 0.000 claims description 3
208000007536 Thrombosis Diseases 0.000 claims description 3
230000033115 angiogenesis Effects 0.000 claims description 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
ZXSLKKNAWCNMEV-SECBINFHSA-N 4-[[(4r)-1-(2,3-dichlorophenyl)-4-methyl-5-oxo-4h-imidazol-2-yl]amino]-3-hydroxybenzonitrile Chemical compound N([C@@H](C(N1C=2C(=C(Cl)C=CC=2)Cl)=O)C)=C1NC1=CC=C(C#N)C=C1O ZXSLKKNAWCNMEV-SECBINFHSA-N 0.000 claims description 2
JDGGLUDGPLPBAQ-HNNXBMFYSA-N 4-[[(4s)-1-(2,3-dichlorophenyl)-4-(2-methylpropyl)-5-oxo-4h-imidazol-2-yl]amino]-3-hydroxybenzonitrile Chemical compound N([C@H](C(N1C=2C(=C(Cl)C=CC=2)Cl)=O)CC(C)C)=C1NC1=CC=C(C#N)C=C1O JDGGLUDGPLPBAQ-HNNXBMFYSA-N 0.000 claims description 2
IEZAVHIASKMLHS-AWEZNQCLSA-N 4-[[(4s)-1-(2,3-dichlorophenyl)-4-(2-methylsulfanylethyl)-5-oxo-4h-imidazol-2-yl]amino]-3-hydroxybenzonitrile Chemical compound N([C@H](C(N1C=2C(=C(Cl)C=CC=2)Cl)=O)CCSC)=C1NC1=CC=C(C#N)C=C1O IEZAVHIASKMLHS-AWEZNQCLSA-N 0.000 claims description 2
ZXSLKKNAWCNMEV-VIFPVBQESA-N 4-[[(4s)-1-(2,3-dichlorophenyl)-4-methyl-5-oxo-4h-imidazol-2-yl]amino]-3-hydroxybenzonitrile Chemical compound N([C@H](C(N1C=2C(=C(Cl)C=CC=2)Cl)=O)C)=C1NC1=CC=C(C#N)C=C1O ZXSLKKNAWCNMEV-VIFPVBQESA-N 0.000 claims description 2
BYJHUMFHEFBZLF-KRWDZBQOSA-N 4-[[(4s)-1-(2,3-dichlorophenyl)-5-oxo-4-propan-2-yl-4h-imidazol-2-yl]amino]-3-hydroxybenzonitrile Chemical compound N([C@H](C(N1C=2C(=C(Cl)C=CC=2)Cl)=O)C(C)C)=C1NC1=CC=C(C#N)C=C1O BYJHUMFHEFBZLF-KRWDZBQOSA-N 0.000 claims description 2
RDCAVUYAUBCYFJ-KRWDZBQOSA-N 4-[[(4s)-1-(2-bromophenyl)-5-oxo-4-propan-2-yl-4h-imidazol-2-yl]amino]-3-hydroxybenzonitrile Chemical compound N([C@H](C(N1C=2C(=CC=CC=2)Br)=O)C(C)C)=C1NC1=CC=C(C#N)C=C1O RDCAVUYAUBCYFJ-KRWDZBQOSA-N 0.000 claims description 2
HNSFHOAPXFLPKT-UHFFFAOYSA-N 4-[[4-(2-bromophenyl)-1,1-dioxo-5h-1,2,4-thiadiazol-3-yl]amino]-3-hydroxybenzonitrile Chemical compound OC1=CC(C#N)=CC=C1NC1=NS(=O)(=O)CN1C1=CC=CC=C1Br HNSFHOAPXFLPKT-UHFFFAOYSA-N 0.000 claims description 2
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
208000024827 Alzheimer disease Diseases 0.000 claims description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
206010009900 Colitis ulcerative Diseases 0.000 claims description 2
208000011231 Crohn disease Diseases 0.000 claims description 2
206010012438 Dermatitis atopic Diseases 0.000 claims description 2
206010018364 Glomerulonephritis Diseases 0.000 claims description 2
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
208000001132 Osteoporosis Diseases 0.000 claims description 2
206010063837 Reperfusion injury Diseases 0.000 claims description 2
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
206010040047 Sepsis Diseases 0.000 claims description 2
206010044248 Toxic shock syndrome Diseases 0.000 claims description 2
231100000650 Toxic shock syndrome Toxicity 0.000 claims description 2
201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 2
201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
206010003246 arthritis Diseases 0.000 claims description 2
208000006673 asthma Diseases 0.000 claims description 2
201000008937 atopic dermatitis Diseases 0.000 claims description 2
SORFPNABQLHFEP-OAHLLOKOSA-N ethyl 2-[(4r)-1-(2-bromophenyl)-2-(4-cyano-2-hydroxyanilino)-5-oxo-4h-imidazol-4-yl]acetate Chemical compound N([C@@H](C(N1C=2C(=CC=CC=2)Br)=O)CC(=O)OCC)=C1NC1=CC=C(C#N)C=C1O SORFPNABQLHFEP-OAHLLOKOSA-N 0.000 claims description 2
ZMTXYOBNYVFVGS-INIZCTEOSA-N ethyl 3-[(4s)-1-(2-bromophenyl)-2-(4-cyano-2-hydroxyanilino)-5-oxo-4h-imidazol-4-yl]propanoate Chemical compound N([C@H](C(N1C=2C(=CC=CC=2)Br)=O)CCC(=O)OCC)=C1NC1=CC=C(C#N)C=C1O ZMTXYOBNYVFVGS-INIZCTEOSA-N 0.000 claims description 2
RRUWPGCBGUELQV-HNNXBMFYSA-N ethyl 3-[(4s)-2-(4-cyano-2-hydroxyanilino)-1-(2,3-dichlorophenyl)-5-oxo-4h-imidazol-4-yl]propanoate Chemical compound N([C@H](C(N1C=2C(=C(Cl)C=CC=2)Cl)=O)CCC(=O)OCC)=C1NC1=CC=C(C#N)C=C1O RRUWPGCBGUELQV-HNNXBMFYSA-N 0.000 claims description 2
208000007565 gingivitis Diseases 0.000 claims description 2
210000003958 hematopoietic stem cell Anatomy 0.000 claims description 2
210000003734 kidney Anatomy 0.000 claims description 2
201000004792 malaria Diseases 0.000 claims description 2
208000037803 restenosis Diseases 0.000 claims description 2
230000036303 septic shock Effects 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
208000024908 graft versus host disease Diseases 0.000 claims 1
102000004890 Interleukin-8 Human genes 0.000 abstract description 55
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 abstract description 53
229940096397 interleukin-8 Drugs 0.000 abstract description 53
238000011282 treatment Methods 0.000 abstract description 15
LUBJCRLGQSPQNN-UHFFFAOYSA-N 1-Phenylurea Chemical compound NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 abstract 2
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
102000016950 Chemokine CXCL1 Human genes 0.000 description 29
-1 GROγ Proteins 0.000 description 25
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
108010014419 Chemokine CXCL1 Proteins 0.000 description 23
102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 22
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 22
210000004027 cell Anatomy 0.000 description 22
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
238000002360 preparation method Methods 0.000 description 21
101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 20
101000973997 Homo sapiens Nucleosome assembly protein 1-like 4 Proteins 0.000 description 20
101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 20
102100036154 Platelet basic protein Human genes 0.000 description 20
210000000440 neutrophil Anatomy 0.000 description 20
239000000243 solution Substances 0.000 description 19
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
238000005481 NMR spectroscopy Methods 0.000 description 16
238000006243 chemical reaction Methods 0.000 description 14
108060008682 Tumor Necrosis Factor Proteins 0.000 description 13
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 13
230000006378 damage Effects 0.000 description 13
239000000203 mixture Substances 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 12
101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 12
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
210000004556 brain Anatomy 0.000 description 12
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 12
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
108020004999 messenger RNA Proteins 0.000 description 12
102000005962 receptors Human genes 0.000 description 12
108020003175 receptors Proteins 0.000 description 12
230000002829 reductive effect Effects 0.000 description 12
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 11
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 11
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 11
230000014509 gene expression Effects 0.000 description 11
239000003960 organic solvent Substances 0.000 description 11
239000007787 solid Substances 0.000 description 11
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 10
102000004127 Cytokines Human genes 0.000 description 10
108090000695 Cytokines Proteins 0.000 description 10
150000001718 carbodiimides Chemical class 0.000 description 10
208000014674 injury Diseases 0.000 description 10
239000012044 organic layer Substances 0.000 description 10
239000011541 reaction mixture Substances 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 9
239000012267 brine Substances 0.000 description 9
238000009472 formulation Methods 0.000 description 9
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
208000027418 Wounds and injury Diseases 0.000 description 8
230000035605 chemotaxis Effects 0.000 description 8
239000000843 powder Substances 0.000 description 8
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 8
102000000589 Interleukin-1 Human genes 0.000 description 7
108010002352 Interleukin-1 Proteins 0.000 description 7
241001465754 Metazoa Species 0.000 description 7
208000030886 Traumatic Brain injury Diseases 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
101001027327 Bos taurus Growth-regulated protein homolog alpha Proteins 0.000 description 6
241000282414 Homo sapiens Species 0.000 description 6
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
210000003169 central nervous system Anatomy 0.000 description 6
230000002757 inflammatory effect Effects 0.000 description 6
102000010681 interleukin-8 receptors Human genes 0.000 description 6
230000000670 limiting effect Effects 0.000 description 6
239000007788 liquid Substances 0.000 description 6
210000002540 macrophage Anatomy 0.000 description 6
230000001936 parietal effect Effects 0.000 description 6
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
238000000746 purification Methods 0.000 description 6
230000004044 response Effects 0.000 description 6
238000010561 standard procedure Methods 0.000 description 6
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
230000009529 traumatic brain injury Effects 0.000 description 6
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 5
102000004889 Interleukin-6 Human genes 0.000 description 5
108090001005 Interleukin-6 Proteins 0.000 description 5
102000016387 Pancreatic elastase Human genes 0.000 description 5
108010067372 Pancreatic elastase Proteins 0.000 description 5
210000001744 T-lymphocyte Anatomy 0.000 description 5
102100040247 Tumor necrosis factor Human genes 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
238000003556 assay Methods 0.000 description 5
239000002585 base Substances 0.000 description 5
208000029028 brain injury Diseases 0.000 description 5
210000002889 endothelial cell Anatomy 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
229940100601 interleukin-6 Drugs 0.000 description 5
108010038415 interleukin-8 receptors Proteins 0.000 description 5
OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 5
210000001616 monocyte Anatomy 0.000 description 5
239000013641 positive control Substances 0.000 description 5
108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
102000013967 Monokines Human genes 0.000 description 4
108010050619 Monokines Proteins 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
230000004913 activation Effects 0.000 description 4
210000003651 basophil Anatomy 0.000 description 4
239000003814 drug Substances 0.000 description 4
229960001484 edetic acid Drugs 0.000 description 4
210000001508 eye Anatomy 0.000 description 4
238000001914 filtration Methods 0.000 description 4
210000001320 hippocampus Anatomy 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
230000008595 infiltration Effects 0.000 description 4
238000001764 infiltration Methods 0.000 description 4
230000000302 ischemic effect Effects 0.000 description 4
150000002540 isothiocyanates Chemical class 0.000 description 4
239000006210 lotion Substances 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
210000003491 skin Anatomy 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 3
KMLPJMZAXCFNNJ-UHFFFAOYSA-N 3-oxo-1,2-benzoxazole-4-carbonitrile Chemical compound C1=CC(C#N)=C2C(=O)NOC2=C1 KMLPJMZAXCFNNJ-UHFFFAOYSA-N 0.000 description 3
ZUQGAUXKKYVVAR-UHFFFAOYSA-N 4-bromo-1,2-benzoxazol-3-one Chemical compound BrC1=CC=CC2=C1C(=O)NO2 ZUQGAUXKKYVVAR-UHFFFAOYSA-N 0.000 description 3
WFAXKTWACQXZQX-UHFFFAOYSA-N C(#N)C1=C(C(=C(C=C1)NC(=S)NC1=C(C=CC=C1)Br)C(C)(C)C)O[SiH](C)C Chemical compound C(#N)C1=C(C(=C(C=C1)NC(=S)NC1=C(C=CC=C1)Br)C(C)(C)C)O[SiH](C)C WFAXKTWACQXZQX-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
235000011054 acetic acid Nutrition 0.000 description 3
230000009471 action Effects 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000008859 change Effects 0.000 description 3
239000002975 chemoattractant Substances 0.000 description 3
230000003399 chemotactic effect Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000004440 column chromatography Methods 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
125000004122 cyclic group Chemical group 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000012530 fluid Substances 0.000 description 3
239000000417 fungicide Substances 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
239000000463 material Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
229910000027 potassium carbonate Inorganic materials 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
GIDMNARLARMVIH-UHFFFAOYSA-N 1-(2-bromophenyl)-3-(4-cyano-2-hydroxyphenyl)thiourea Chemical compound OC1=CC(C#N)=CC=C1NC(=S)NC1=CC=CC=C1Br GIDMNARLARMVIH-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
HKZPOGZBKIWMPO-UHFFFAOYSA-N 4-amino-3-hydroxybenzonitrile Chemical compound NC1=CC=C(C#N)C=C1O HKZPOGZBKIWMPO-UHFFFAOYSA-N 0.000 description 2
229960000549 4-dimethylaminophenol Drugs 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
101001069913 Bos taurus Growth-regulated protein homolog beta Proteins 0.000 description 2
101001069912 Bos taurus Growth-regulated protein homolog gamma Proteins 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
SIFHFOLMIBTJDT-UHFFFAOYSA-N C(#N)C1=C(C(=C(C=C1)N=C=NC1=C(C=CC=C1)Br)C(C)(C)C)O[SiH](C)C Chemical compound C(#N)C1=C(C(=C(C=C1)N=C=NC1=C(C=CC=C1)Br)C(C)(C)C)O[SiH](C)C SIFHFOLMIBTJDT-UHFFFAOYSA-N 0.000 description 2
102100036189 C-X-C motif chemokine 3 Human genes 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
208000018652 Closed Head injury Diseases 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000947193 Homo sapiens C-X-C motif chemokine 3 Proteins 0.000 description 2
101500025785 Homo sapiens IL-8(6-77) Proteins 0.000 description 2
101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
102400001232 IL-8(6-77) Human genes 0.000 description 2
102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
239000012359 Methanesulfonyl chloride Substances 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
108010025020 Nerve Growth Factor Proteins 0.000 description 2
102000015336 Nerve Growth Factor Human genes 0.000 description 2
238000000636 Northern blotting Methods 0.000 description 2
235000019483 Peanut oil Nutrition 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
239000003899 bactericide agent Substances 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
239000000872 buffer Substances 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
229910002091 carbon monoxide Inorganic materials 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
239000005482 chemotactic factor Substances 0.000 description 2
DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 2
239000006071 cream Substances 0.000 description 2
238000011161 development Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
210000005069 ears Anatomy 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000003511 endothelial effect Effects 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
230000003394 haemopoietic effect Effects 0.000 description 2
210000003128 head Anatomy 0.000 description 2
125000005343 heterocyclic alkyl group Chemical group 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000003993 interaction Effects 0.000 description 2
230000021995 interleukin-8 production Effects 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
150000003951 lactams Chemical class 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
CMEUDEVBFFPSEI-NFHWZJRKSA-N methyl 4-[[(2s)-1-[[(2s)-1-[(2s)-2-[[(2s)-3-methyl-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoate Chemical compound COC(=O)CCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NC1=CC=C(C(C)=CC(=O)O2)C2=C1 CMEUDEVBFFPSEI-NFHWZJRKSA-N 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
239000013642 negative control Substances 0.000 description 2
229940053128 nerve growth factor Drugs 0.000 description 2
230000011242 neutrophil chemotaxis Effects 0.000 description 2
210000001331 nose Anatomy 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000004006 olive oil Substances 0.000 description 2
235000008390 olive oil Nutrition 0.000 description 2
239000006072 paste Substances 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
229960001412 pentobarbital Drugs 0.000 description 2
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
229920000515 polycarbonate Polymers 0.000 description 2
239000004417 polycarbonate Substances 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
238000001525 receptor binding assay Methods 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
239000000523 sample Substances 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000012453 sprague-dawley rat model Methods 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
230000002123 temporal effect Effects 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000010474 transient expression Effects 0.000 description 2
230000008733 trauma Effects 0.000 description 2
TXTWXQXDMWILOF-UHFFFAOYSA-N (2-ethoxy-2-oxoethyl)azanium;chloride Chemical compound [Cl-].CCOC(=O)C[NH3+] TXTWXQXDMWILOF-UHFFFAOYSA-N 0.000 description 1
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
CUVLPRMPYJQDPQ-UHFFFAOYSA-N (4-cyano-2-hydroxyanilino) 3,3-dimethylbutanoate Chemical compound CC(C)(C)CC(=O)ONC1=CC=C(C#N)C=C1O CUVLPRMPYJQDPQ-UHFFFAOYSA-N 0.000 description 1
GGYWCOWJACHOOL-UHFFFAOYSA-N (4-cyano-3-oxo-1,2-benzoxazol-2-yl) 3,3-dimethylbutanoate Chemical compound C1=CC=C(C#N)C2=C1ON(OC(=O)CC(C)(C)C)C2=O GGYWCOWJACHOOL-UHFFFAOYSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
OWRCNXZUPFZXOS-UHFFFAOYSA-N 1,3-diphenylguanidine Chemical compound C=1C=CC=CC=1NC(=N)NC1=CC=CC=C1 OWRCNXZUPFZXOS-UHFFFAOYSA-N 0.000 description 1
KCOPAESEGCGTKM-UHFFFAOYSA-N 1,3-oxazol-4-one Chemical compound O=C1COC=N1 KCOPAESEGCGTKM-UHFFFAOYSA-N 0.000 description 1
WPRAXAOJIODQJR-UHFFFAOYSA-N 1-(3,4-dimethylphenyl)ethanone Chemical compound CC(=O)C1=CC=C(C)C(C)=C1 WPRAXAOJIODQJR-UHFFFAOYSA-N 0.000 description 1
KEMUANCPFSTFMI-UHFFFAOYSA-N 1-(4-cyano-2-hydroxyphenyl)-3-(2-hydroxyphenyl)thiourea Chemical compound C(#N)C1=CC(=C(C=C1)NC(=S)NC1=C(C=CC=C1)O)O KEMUANCPFSTFMI-UHFFFAOYSA-N 0.000 description 1
PAFORXDSYWMYGP-UHFFFAOYSA-N 1-bromo-2-isothiocyanatobenzene Chemical compound BrC1=CC=CC=C1N=C=S PAFORXDSYWMYGP-UHFFFAOYSA-N 0.000 description 1
125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
125000006017 1-propenyl group Chemical group 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
QKWWDTYDYOFRJL-UHFFFAOYSA-N 2,2-dimethoxyethanamine Chemical compound COC(CN)OC QKWWDTYDYOFRJL-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
CHZCERSEMVWNHL-UHFFFAOYSA-N 2-hydroxybenzonitrile Chemical compound OC1=CC=CC=C1C#N CHZCERSEMVWNHL-UHFFFAOYSA-N 0.000 description 1
125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
SGHBRHKBCLLVCI-UHFFFAOYSA-N 3-hydroxybenzonitrile Chemical compound OC1=CC=CC(C#N)=C1 SGHBRHKBCLLVCI-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
102000040717 Alpha family Human genes 0.000 description 1
108091071248 Alpha family Proteins 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
206010003645 Atopy Diseases 0.000 description 1
125000006847 BOC protecting group Chemical group 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
108700012434 CCL3 Proteins 0.000 description 1
108050006947 CXC Chemokine Proteins 0.000 description 1
102000019388 CXC chemokine Human genes 0.000 description 1
101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 description 1
108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
206010051290 Central nervous system lesion Diseases 0.000 description 1
102000000013 Chemokine CCL3 Human genes 0.000 description 1
229940122444 Chemokine receptor antagonist Drugs 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
101000818522 Homo sapiens fMet-Leu-Phe receptor Proteins 0.000 description 1
WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102100022338 Integrin alpha-M Human genes 0.000 description 1
102100025390 Integrin beta-2 Human genes 0.000 description 1
102000003777 Interleukin-1 beta Human genes 0.000 description 1
108090000193 Interleukin-1 beta Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
239000004909 Moisturizer Substances 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
210000001056 activated astrocyte Anatomy 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000009692 acute damage Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
235000020224 almond Nutrition 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
239000012300 argon atmosphere Substances 0.000 description 1
210000001130 astrocyte Anatomy 0.000 description 1
239000005667 attractant Substances 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
229960004365 benzoic acid Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000004271 bone marrow stromal cell Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
230000031709 bromination Effects 0.000 description 1
238000005893 bromination reaction Methods 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
125000004799 bromophenyl group Chemical group 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical class O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000036978 cell physiology Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000031902 chemoattractant activity Effects 0.000 description 1
239000002559 chemokine receptor antagonist Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
229960002152 chlorhexidine acetate Drugs 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
AVXHCUKQISJQBN-UHFFFAOYSA-N chloromethanesulfonamide Chemical compound NS(=O)(=O)CCl AVXHCUKQISJQBN-UHFFFAOYSA-N 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000005352 clarification Methods 0.000 description 1
239000004927 clay Substances 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000013058 crude material Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000006196 drop Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000005175 epidermal keratinocyte Anatomy 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
238000004880 explosion Methods 0.000 description 1
102100021145 fMet-Leu-Phe receptor Human genes 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
229960002598 fumaric acid Drugs 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000000855 fungicidal effect Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000002357 guanidines Chemical class 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
125000005553 heteroaryloxy group Chemical group 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
239000011539 homogenization buffer Substances 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
125000004356 hydroxy functional group Chemical class O* 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
239000011147 inorganic material Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
230000003902 lesion Effects 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
229940098895 maleic acid Drugs 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000004452 microanalysis Methods 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000001333 moisturizer Effects 0.000 description 1
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
QFOGKEHRJOUASD-UHFFFAOYSA-N n-(diaminomethylidene)-1h-imidazole-2-carboxamide Chemical compound NC(=N)NC(=O)C1=NC=CN1 QFOGKEHRJOUASD-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
RIVIDPPYRINTTH-UHFFFAOYSA-N n-ethylpropan-2-amine Chemical compound CCNC(C)C RIVIDPPYRINTTH-UHFFFAOYSA-N 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
229920001206 natural gum Polymers 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
235000020232 peanut Nutrition 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000003279 phenylacetic acid Substances 0.000 description 1
229960003424 phenylacetic acid Drugs 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
239000001294 propane Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
239000000376 reactant Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000019254 respiratory burst Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000000344 soap Substances 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
239000011345 viscous material Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1
210000002268 wool Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Transplantation (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

KR1020017015176A 1999-05-28 2000-05-26 Ｉｌ-8 수용체 길항제 Withdrawn KR20020016806A (ko)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US13666599P	1999-05-28	1999-05-28
US60/136,665		1999-05-28
PCT/US2000/014660 WO2000072840A1 (en)	1999-05-28	2000-05-26	Il-8 receptor antagonists

Publications (1)

Publication Number	Publication Date
KR20020016806A true KR20020016806A (ko)	2002-03-06

Family

ID=22473833

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1020017015176A Withdrawn KR20020016806A (ko)	1999-05-28	2000-05-26	Ｉｌ-8 수용체 길항제

Country Status (20)

Country	Link
EP (1)	EP1180025A4 (no)
JP (1)	JP2003500443A (no)
KR (1)	KR20020016806A (no)
CN (1)	CN1352554A (no)
AR (1)	AR029361A1 (no)
AU (1)	AU766999B2 (no)
BR (1)	BR0010863A (no)
CA (1)	CA2374295A1 (no)
CO (1)	CO5170528A1 (no)
CZ (1)	CZ20014246A3 (no)
HK (1)	HK1045256A1 (no)
HU (1)	HUP0201302A3 (no)
IL (1)	IL146053A0 (no)
MX (1)	MXPA01012267A (no)
NO (1)	NO20015774L (no)
NZ (1)	NZ514728A (no)
PL (1)	PL351947A1 (no)
TR (1)	TR200103354T2 (no)
WO (1)	WO2000072840A1 (no)
ZA (1)	ZA200109627B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6875759B1 (en)	1999-07-21	2005-04-05	Kadmus Pharmaceuticals	Substituted guanidines and the use thereof
WO2001007029A2 (en) *	1999-07-21	2001-02-01	Kadmus Pharmaceuticals, Inc.	Substituted guanidines and the use thereof
EP1413302A3 (en) *	1999-07-21	2004-05-12	Kadmus Pharmaceuticals, Inc.	Substituted guanidines for the treatment of pain
WO2002070467A1 (en)	2001-02-26	2002-09-12	4Sc Ag	Derivatives of diphenylurea, diphenyloxalic acid diamide and diphenylsulfuric acid diamide and their use as medicaments
DE10109204A1 (de) *	2001-02-26	2002-09-19	4Sc Ag	Verbindungen zur Behandlung von Protozoen-Erkrankungen
JP2006525254A (ja)	2003-05-01	2006-11-09	エフ．ホフマン−ラ　ロシュ　アーゲー	Ｉｐアンタゴニストとしてのイミダゾリン−２−イルアミノ−フェニルアミド類
CN101531621B (zh) *	2009-04-14	2012-08-15	厦门康奥克科技有限公司	一种胍类化合物的制备方法
CA3079959A1 (en) *	2017-10-27	2018-10-26	Transfusion Health, Llc	Compositions and methods of making expanded hematopoietic stem cells using derivatives of fluorene

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US605977A (en) *		1898-06-21		Bruno richard seifert
US1953494A (en) *	1926-08-26	1934-04-03	Ig Farbenindustrie Ag	Process of preparing substituted guanidines
US3914306A (en) *	1972-09-22	1975-10-21	Rorer Inc William H	Guanidines
US5696290A (en) *	1994-09-12	1997-12-09	Monsanto Company	Synthesis of penta-substituted guanidines
JPH11503110A (ja) *	1995-02-17	1999-03-23	スミスクライン・ビーチャム・コーポレイション	Ｉｌ−８受容体拮抗剤
AR008290A1 (es) *	1996-08-15	1999-12-29	Smithkline Beecham Corp	Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios.
WO2000072800A2 (en) *	1999-05-28	2000-12-07	Smithkline Beecham Corporation	Il-8 receptor antagonists
UY26627A1 (es) *	2000-03-24	2001-09-28	Smithkline Beecham Corp	Antagonistas de receptores de il-8

2000
- 2000-05-24 CO CO00038191A patent/CO5170528A1/es not_active Application Discontinuation
- 2000-05-24 AR ARP000102556A patent/AR029361A1/es unknown
- 2000-05-26 CZ CZ20014246A patent/CZ20014246A3/cs unknown
- 2000-05-26 KR KR1020017015176A patent/KR20020016806A/ko not_active Withdrawn
- 2000-05-26 JP JP2000620952A patent/JP2003500443A/ja not_active Withdrawn
- 2000-05-26 HK HK02105335.1A patent/HK1045256A1/zh unknown
- 2000-05-26 IL IL14605300A patent/IL146053A0/xx unknown
- 2000-05-26 TR TR2001/03354T patent/TR200103354T2/xx unknown
- 2000-05-26 AU AU51690/00A patent/AU766999B2/en not_active Ceased
- 2000-05-26 EP EP00936368A patent/EP1180025A4/en not_active Withdrawn
- 2000-05-26 PL PL00351947A patent/PL351947A1/xx not_active Application Discontinuation
- 2000-05-26 CN CN00808133A patent/CN1352554A/zh active Pending
- 2000-05-26 NZ NZ514728A patent/NZ514728A/en not_active Application Discontinuation
- 2000-05-26 CA CA002374295A patent/CA2374295A1/en not_active Abandoned
- 2000-05-26 BR BR0010863-4A patent/BR0010863A/pt not_active IP Right Cessation
- 2000-05-26 WO PCT/US2000/014660 patent/WO2000072840A1/en not_active Ceased
- 2000-05-26 HU HU0201302A patent/HUP0201302A3/hu unknown
- 2000-05-26 MX MXPA01012267A patent/MXPA01012267A/es unknown
2001
- 2001-11-22 ZA ZA200109267A patent/ZA200109627B/xx unknown
- 2001-11-27 NO NO20015774A patent/NO20015774L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
MXPA01012267A (es)	2002-07-30
HUP0201302A2 (hu)	2002-12-28
CZ20014246A3 (cs)	2002-05-15
JP2003500443A (ja)	2003-01-07
NO20015774D0 (no)	2001-11-27
CA2374295A1 (en)	2000-12-07
ZA200109627B (en)	2002-11-28
PL351947A1 (en)	2003-07-14
BR0010863A (pt)	2002-02-19
TR200103354T2 (tr)	2002-06-21
EP1180025A1 (en)	2002-02-20
HUP0201302A3 (en)	2003-02-28
AR029361A1 (es)	2003-06-25
EP1180025A4 (en)	2002-08-28
IL146053A0 (en)	2002-07-25
AU5169000A (en)	2000-12-18
WO2000072840A1 (en)	2000-12-07
HK1045256A1 (zh)	2002-11-22
CO5170528A1 (es)	2002-06-27
NZ514728A (en)	2004-04-30
CN1352554A (zh)	2002-06-05
AU766999B2 (en)	2003-10-30
NO20015774L (no)	2001-11-27

Publication	Publication Date	Title
US6218539B1 (en)	2001-04-17	IL-8 receptor antagonists
KR20000070368A (ko)	2000-11-25	인터루킨-8 수용체 길항제
US6204294B1 (en)	2001-03-20	IL-8 receptor antagonists
KR20000022273A (ko)	2000-04-25	Il-8 수용체 길항제
KR20000022274A (ko)	2000-04-25	Il-8 수용체 길항제
KR20030017526A (ko)	2003-03-03	Ｉｌ-８ 수용체 길항제
JP2000513359A (ja)	2000-10-10	Ｉｌ―８受容体拮抗薬
EP1261328B1 (en)	2005-07-20	Il-8 receptor antagonists
US6166055A (en)	2000-12-26	Benzoisothiazole compounds useful as IL-8 receptor antagonists
KR20020010674A (ko)	2002-02-04	Ｉｌ-8 수용체 길항제
EP0971908B1 (en)	2004-06-30	Il-8 receptor antagonists
KR20020016806A (ko)	2002-03-06	Ｉｌ-8 수용체 길항제
JP2003525302A (ja)	2003-08-26	Ｉｌ−８受容体アンタゴニスト
US6248785B1 (en)	2001-06-19	IL-8 receptor antagonists
US6436927B1 (en)	2002-08-20	IL-8 receptor antagonists
US6221889B1 (en)	2001-04-24	IL-8 receptor antagonists
WO2000072800A2 (en)	2000-12-07	Il-8 receptor antagonists
JP2000515495A (ja)	2000-11-21	Ｉｌ―８レセプターアンタゴニスト
JP2003501450A (ja)	2003-01-14	Ｉｌ−８受容体アンタゴニスト
WO2000073282A1 (en)	2000-12-07	Il-8 receptor antagonists
KR20020091127A (ko)	2002-12-05	Ｉｌ-8 수용체 길항제
CZ257999A3 (cs)	2000-01-12	Antagonista IL-8 receptoru

Legal Events

Date	Code	Title	Description
2001-11-27	PA0105	International application	Patent event date: 20011127 Patent event code: PA01051R01D Comment text: International Patent Application
2002-03-06	PG1501	Laying open of application
2005-05-27	PC1203	Withdrawal of no request for examination
2005-05-27	WITN	Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid